Lowering LDL cholesterol is good, but how and in whom?
- PMID: 25773740
- DOI: 10.1056/NEJMe1502192
Lowering LDL cholesterol is good, but how and in whom?
Comment on
-
Efficacy and safety of alirocumab in reducing lipids and cardiovascular events.N Engl J Med. 2015 Apr 16;372(16):1489-99. doi: 10.1056/NEJMoa1501031. Epub 2015 Mar 15. N Engl J Med. 2015. PMID: 25773378 Clinical Trial.
-
Efficacy and safety of evolocumab in reducing lipids and cardiovascular events.N Engl J Med. 2015 Apr 16;372(16):1500-9. doi: 10.1056/NEJMoa1500858. Epub 2015 Mar 15. N Engl J Med. 2015. PMID: 25773607 Clinical Trial.
Similar articles
-
Dyslipidaemia. Assessing the efficacy and safety of evolocumab and alirocumab.Nat Rev Cardiol. 2015 May;12(5):261. doi: 10.1038/nrcardio.2015.51. Epub 2015 Mar 31. Nat Rev Cardiol. 2015. PMID: 25824512 No abstract available.
-
PCSK9 Inhibitors and Cardiovascular Events.N Engl J Med. 2015 Aug 20;373(8):773. doi: 10.1056/NEJMc1508222. N Engl J Med. 2015. PMID: 26287855 No abstract available.
-
PCSK9 Inhibitors and Cardiovascular Events.N Engl J Med. 2015 Aug 20;373(8):774. doi: 10.1056/NEJMc1508222. N Engl J Med. 2015. PMID: 26287854 No abstract available.
-
New Drugs for Lowering LDL-Cholesterol.Rev Med Chir Soc Med Nat Iasi. 2016 Jul-Sep;120(3):485-90. Rev Med Chir Soc Med Nat Iasi. 2016. PMID: 30044561 Review.
-
New LDL-cholesterol lowering therapies: pharmacology, clinical trials, and relevance to acute coronary syndromes.Clin Ther. 2013 Aug;35(8):1082-98. doi: 10.1016/j.clinthera.2013.06.019. Epub 2013 Aug 8. Clin Ther. 2013. PMID: 23932550 Review.
Cited by
-
Immunomodulatory Nanomedicine for the Treatment of Atherosclerosis.J Clin Med. 2021 Jul 20;10(14):3185. doi: 10.3390/jcm10143185. J Clin Med. 2021. PMID: 34300351 Free PMC article. Review.
-
G-Protein Coupled Receptor Targeting on Myeloid Cells in Atherosclerosis.Front Pharmacol. 2019 May 22;10:531. doi: 10.3389/fphar.2019.00531. eCollection 2019. Front Pharmacol. 2019. PMID: 31191301 Free PMC article. Review.
-
ANMCO/ISS/AMD/ANCE/ARCA/FADOI/GICR-IACPR/SICI-GISE/SIBioC/SIC/SICOA/SID/SIF/SIMEU/SIMG/SIMI/SISA Joint Consensus Document on cholesterol and cardiovascular risk: diagnostic-therapeutic pathway in Italy.Eur Heart J Suppl. 2017 May;19(Suppl D):D3-D54. doi: 10.1093/eurheartj/sux029. Epub 2017 May 2. Eur Heart J Suppl. 2017. PMID: 28751833 Free PMC article.
-
Low Density Lipoproteins Amplify Cytokine-signaling in Chronic Lymphocytic Leukemia Cells.EBioMedicine. 2017 Feb;15:24-35. doi: 10.1016/j.ebiom.2016.11.033. Epub 2016 Nov 30. EBioMedicine. 2017. PMID: 27932296 Free PMC article.
-
[National disease management guidelines (NVL) for chronic CAD : What is new, what is particularly important?].Herz. 2016 Sep;41(6):537-60. doi: 10.1007/s00059-016-4474-9. Herz. 2016. PMID: 27586137 Review. German.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical